CN109069504B - 氨基噻唑化合物及其用途 - Google Patents

氨基噻唑化合物及其用途 Download PDF

Info

Publication number
CN109069504B
CN109069504B CN201780010118.4A CN201780010118A CN109069504B CN 109069504 B CN109069504 B CN 109069504B CN 201780010118 A CN201780010118 A CN 201780010118A CN 109069504 B CN109069504 B CN 109069504B
Authority
CN
China
Prior art keywords
cancer
compound
compounds
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780010118.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069504A (zh
Inventor
姜韦汤
许楚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
Taiwan Institute Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Institute Of Health filed Critical Taiwan Institute Of Health
Publication of CN109069504A publication Critical patent/CN109069504A/zh
Application granted granted Critical
Publication of CN109069504B publication Critical patent/CN109069504B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201780010118.4A 2016-02-05 2017-01-31 氨基噻唑化合物及其用途 Active CN109069504B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291667P 2016-02-05 2016-02-05
US62/291,667 2016-02-05
PCT/US2017/015765 WO2017136315A1 (en) 2016-02-05 2017-01-31 Aminothiazole compounds and use thereof

Publications (2)

Publication Number Publication Date
CN109069504A CN109069504A (zh) 2018-12-21
CN109069504B true CN109069504B (zh) 2022-06-28

Family

ID=59496120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780010118.4A Active CN109069504B (zh) 2016-02-05 2017-01-31 氨基噻唑化合物及其用途

Country Status (8)

Country Link
US (1) US10047078B2 (OSRAM)
EP (1) EP3411035B1 (OSRAM)
JP (1) JP6883049B2 (OSRAM)
KR (1) KR102449712B1 (OSRAM)
CN (1) CN109069504B (OSRAM)
ES (1) ES2909612T3 (OSRAM)
TW (1) TWI620748B (OSRAM)
WO (1) WO2017136315A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7301958B2 (ja) 2018-05-25 2023-07-03 オンコキューブ セラピューティクス エルエルシー 新規な抗がん薬候補としての非常に強力なｔａｃｃ３阻害剤
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
US20240374590A1 (en) * 2021-04-12 2024-11-14 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
TW202400575A (zh) 2022-03-24 2024-01-01 美商Ａ２Ａ製藥公司 治療癌症的組合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
US20130150364A1 (en) * 2010-08-10 2013-06-13 Astellas Pharma Inc. Heterocyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
DK1347971T3 (da) * 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
WO2004041164A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
US20090105250A1 (en) * 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
HUE025179T2 (en) 2008-04-21 2016-02-29 Taigen Biotechnology Co Ltd Heterocyclic Compounds
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150364A1 (en) * 2010-08-10 2013-06-13 Astellas Pharma Inc. Heterocyclic compound
US20120225880A1 (en) * 2011-03-04 2012-09-06 National Health Research Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors

Also Published As

Publication number Publication date
ES2909612T3 (es) 2022-05-09
EP3411035B1 (en) 2022-03-02
TW201728583A (zh) 2017-08-16
JP2019511564A (ja) 2019-04-25
EP3411035A4 (en) 2019-08-14
CN109069504A (zh) 2018-12-21
KR102449712B1 (ko) 2022-09-30
WO2017136315A1 (en) 2017-08-10
US20170226100A1 (en) 2017-08-10
US10047078B2 (en) 2018-08-14
TWI620748B (zh) 2018-04-11
HK1258689A1 (zh) 2019-11-15
KR20180132618A (ko) 2018-12-12
JP6883049B2 (ja) 2021-06-02
EP3411035A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
CN109069504B (zh) 氨基噻唑化合物及其用途
KR102618773B1 (ko) 디아릴 거대환형 화합물을 수반하는 병용 요법
JP7058345B2 (ja) Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
TW202007396A (zh) Bcl-2抑制劑或Bcl-2/Bcl-xL抑制劑與BTK抑制劑的組合產品及其在預防和/或治療疾病中的用途
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
KR20100135754A (ko) 병용 요법 238
SG178351A1 (en) Compounds and compositions as protein kinase inhibitors
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
AU2022201717B2 (en) Treatment of cancer
CN114901286B (zh) 涉及二芳基巨环化合物的组合疗法
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
KR20240004548A (ko) 암 치료를 위한 pcna 억제제 및 egfr 억제제
WO2015112705A2 (en) Therapeutic combinations for treating cancer
CN112237579B (zh) 药物组合及其用途
HK1258689B (en) Aminothiazole compounds and use thereof
JP7200453B2 (ja) Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体
JP2014034531A (ja) Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
HK40035225A (en) Pharmaceutical combination and use thereof
EP4441052A1 (en) Compounds
HK40017909A (en) Aminothiazole compounds as protein kinase inhibitors
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190325

Address after: Miaoli County, Taiwan, China

Applicant after: National Health Research Institutes

Address before: Miaoli County, Taiwan, China

Applicant before: National Health Research Institutes

Applicant before: Shi Quan

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258689

Country of ref document: HK

CB02 Change of applicant information

Address after: Miaoli County, Taiwan, China

Applicant after: Taiwan Institute of health

Address before: Miaoli County, Taiwan, China

Applicant before: NATIONAL HEALTH RESEARCH INSTITUTES

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: Jiang Weitang

Inventor after: Xu Shi

Inventor before: Jiang Weitang

Inventor before: Xu Chu

CB03 Change of inventor or designer information